Last reviewed · How we verify
Kisspeptin 112-121 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Kisspeptin 112-121 (Kisspeptin 112-121) — Stephanie B. Seminara, MD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Kisspeptin 112-121 TARGET | Kisspeptin 112-121 | Stephanie B. Seminara, MD | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Kisspeptin 112-121 CI watch — RSS
- Kisspeptin 112-121 CI watch — Atom
- Kisspeptin 112-121 CI watch — JSON
- Kisspeptin 112-121 alone — RSS
Cite this brief
Drug Landscape (2026). Kisspeptin 112-121 — Competitive Intelligence Brief. https://druglandscape.com/ci/kisspeptin-112-121. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab